Radiosensitization of cancer cells by inactivation of cullin- RING E3 ubiquitin ligases

Translational Oncology

Volumn 5, Issue 5, 2012, Pages 305-312

  Wei, Dongping ^a   Morgan, Meredith A ^a   Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CULLIN BASED RING E3 UBIQUITIN LIGASE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DELANZOMIB; F BOX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IXAZOMIB CITRATE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEDD8 PROTEIN; PROTEASOME; PROTEIN NOXA; RING BOX PROTEIN 1; RING BOX PROTEIN 2; RING FINGER PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SALINOSPORAMIDE A; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; [4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER RADIOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CELL SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SUBUNIT; ESOPHAGUS CANCER; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GLIOMA; HODGKIN DISEASE; HUMAN; LIVER CANCER; LUNG CANCER; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NEDDYLATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; RADIOSENSITIZATION; RECTUM CANCER; REVIEW; STOMACH CANCER; UBIQUITINATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

EID: 84867534504     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12229     Document Type: Article

References (131)

1. Begg AC, Stewart FA, and Vens C (2011). Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11, 239-253.
2. Delaney G, Jacob S, Featherstone C, and Barton M (2005). The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104, 1129-1137.
3. Bhide SA and Nutting CM (2010). Recent advances in radiotherapy. BMC Med 8, 25.
4. Hershko A and Ciechanover A (1998). The ubiquitin system. Annu Rev Biochem 67, 425-479.
5. Keating SE and Bowie AG (2009). Role of non-degradative ubiquitination in interleukin-1 and toll-like receptor signaling. J Biol Chem 284, 8211-8215.
6. Edelmann MJ, Nicholson B, and Kessler BM (2011). Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med 13, e35.
7. Strieter ER and Korasick DA (2012). Unraveling the complexity of ubiquitin signaling. ACS Chem Biol 7, 52-63.
8. Deshaies RJ and Joazeiro CA (2009). RING domain E3 ubiquitin ligases. Annu Rev Biochem 78, 399-434.
9. Jia L and Sun Y (2011). SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets 11, 347-356.
10. Sun Y (2006). E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8, 645-654.
11. Kang C and Yi GS (2011). Identification of ubiquitin/ubiquitin-like protein modification from tandem mass spectra with various PTMs. BMC Bioinformatics 12(suppl 14), S8.
12. Kerscher O, Felberbaum R, and Hochstrasser M (2006). Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22, 159-180.
13. Pickart CM (2001). Ubiquitin enters the new millennium. Mol Cell 8, 499-504.
14. Chen ZJ and Sun LJ (2009). Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 33, 275-286.
15. Skaug B, Jiang X, and Chen ZJ (2009). The role of ubiquitin in NF-κB regulatory pathways. Annu Rev Biochem 78, 769-796.
16. Bennett EJ and Harper JW (2008). DNA damage: ubiquitin marks the spot. Nat Struct Mol Biol 15, 20-22.
17. Ulrich HD and Walden H (2010). Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Biol 11, 479-489.
18. Acconcia F, Sigismund S, and Polo S (2009). Ubiquitin in trafficking: the network at work. Exp Cell Res 315, 1610-1618.
19. Ye Y and Rape M (2009). Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol 10, 755-764.
20. Bernassola F, Karin M, Ciechanover A, and Melino G (2008). The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14, 10-21.
21. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al. (2009). An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736.
22. Sarikas A, Hartmann T, and Pan ZQ (2011). The cullin protein family. Genome Biol 12, 220.
23. Duan H, Wang Y, Aviram M, Swaroop M, Loo JA, Bian J, Tian Y, Mueller T, Bisgaier CL, and Sun Y (1999). SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol Cell Biol 19, 3145-3155.
24. Sun Y, Tan M, Duan H, and Swaroop M (2001). SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid Redox Signal 3, 635-650.
25. Ohta T, Michel JJ, and Xiong Y (1999). Association with cullin partners protects ROC proteins from proteasome-dependent degradation. Oncogene 18, 6758-6766.
26. Swaroop M, Wang Y, Miller P, Duan H, Jatkoe T, Madore S, and Sun Y (2000). Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: chip profiling implicates its role in cell cycle regulation. Oncogene 19, 2855-2866.
27. Wei D and Sun Y (2010). Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets. Genes Cancer 1, 700-707.
28. Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW, and Nakayama KI (2004). VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18, 3055-3065.
29. Deshaies RJ (1999). SCF and cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15, 435-467.
30. Feldman RM, Correll CC, Kaplan KB, and Deshaies RJ (1997). A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91, 221-230.
31. Skowyra D, Craig KL, Tyers M, Elledge SJ, and Harper JW (1997). F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91, 209-219.
32. Petroski MD and Deshaies RJ (2005). Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6, 9-20.
33. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al. (2002). Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416, 703-709.
34. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, and Harper JW (2004). Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18, 2573-2580.
35. Pan ZQ, Kentsis A, Dias DC, Yamoah K, and Wu K (2004). Nedd8 on cullin: building an expressway to protein destruction. Oncogene 23, 1985-1997.
36. Rabut G and Peter M (2008). Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 9, 969-976.
37. Xirodimas DP (2008). Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem Soc Trans 36, 802-806.
38. Deshaies RJ, Emberley ED, and Saha A (2010). Control of cullin-RING ubiquitin ligase activity by Nedd8. In Conjugation and Deconjugation of Ubiquitin Family Modifiers: Subcellular Biochemistry. M Groettrup (Ed). Springer, NY. Vol. 54. pp. 41-56.
39. Merlet J, Burger J, Gomes JE, and Pintard L (2009). Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization. Cell Mol Life Sci 66, 1924-1938.
40. Gong L and Yeh ET (1999). Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem 274, 12036-12042.
41. Liakopoulos D, Doenges G, Matuschewski K, and Jentsch S (1998). A novel protein modification pathway related to the ubiquitin system. EMBO J 17, 2208-2214.
42. Osaka F, Kawasaki H, Aida N, Saeki M, Chiba T, Kawashima S, Tanaka K, and Kato S (1998). A new NEDD8-ligating system for cullin-4A. Genes Dev 12, 2263-2268.
43. Huang DT, Ayrault O, Hunt HW, Taherbhoy AM, Duda DM, Scott DC, Borg LA, Neale G, Murray PJ, Roussel MF, et al. (2009). E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell 33, 483-495.
44. Kamura T, Conrad MN, Yan Q, Conaway RC, and Conaway JW (1999). The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 13, 2928-2933.
45. MorimotoM, Nishida T, Nagayama Y, and YasudaH(2003). Nedd8-modification of Cul1 is promoted by Roc1 as a Nedd8-E3 ligase and regulates its stability. Biochem Biophys Res Commun 301, 392-398.
46. Yang X, Zhou J, Sun L, Wei Z, Gao J, Gong W, Xu RM, Rao Z, and Liu Y (2007). Structural basis for the function of DCN-1 in protein neddylation. J Biol Chem 282, 24490-24494.
47. Broemer M, Tenev T, Rigbolt KT, Hempel S, Blagoev B, Silke J, Ditzel M, and Meier P (2010). Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases. Mol Cell 40, 810-822.
48. Nalepa G, Rolfe M, and Harper JW (2006). Drug discovery in the ubiquitinproteasome system. Nat Rev Drug Discov 5, 596-613.
49. Chen D, Frezza M, Schmitt S, Kanwar J, and Dou QP (2011). Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11, 239-253.
50. Kane RC, Bross PF, Farrell AT, and Pazdur R (2003). Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508-513.
51. Bedford L, Lowe J, Dick LR, Mayer RJ, and Brownell JE (2011). Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 10, 29-46.
52. Orlowski RZ and Kuhn DJ (2008). Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14, 1649-1657.
53. Richardson PG, Mitsiades C, Hideshima T, and Anderson KC (2006). Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57, 33-47.
54. Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, and Kelsen DP (2011). A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 29, 1475-1481.
55. Pajonk F, Pajonk K, and McBride WH (2000). Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 47, 1025-1032.
56. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, and Cusack JC Jr (2001). Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 50, 183-193.
57. Motegi A, Murakawa Y, and Takeda S (2009). The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. Cancer Lett 283, 1-9.
58. Lioni M, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, Herlyn M, and Smalley KS (2008). Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther 7, 2866-2875.
59. Kamer S, Ren Q, and Dicker AP (2009). Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). Arch Gynecol Obstet 279, 41-46.
60. Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL, and Chen KF (2012). Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett 317, 9-15.
61. Grimes KR, Daosukho C, Zhao Y, Meigooni A, and St Clair W (2005). Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection. Int J Oncol 27, 1047-1052.
62. Pajonk F, van Ophoven A, Weissenberger C, and McBride WH (2005). The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer 5, 76.
63. Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, McBride WH, and Pajonk F (2010). Differential effects of the proteasome inhibitor NPI-0052 against glioma cells. Transl Oncol 3, 50-55.
64. O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, et al. (2010). A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer 9, 119-125.
65. Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R, and Suntharalingam M (2010). Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in stage III non-small cell lung cancer. Lung Cancer 68, 84-88.
66. Nakayama KI and Nakayama K (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6, 369-381.
67. Frescas D and Pagano M (2008). Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat Rev Cancer 8, 438-449.
68. WelckerMand Clurman BE (2008). FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8, 83-93.
69. Huang Y, Duan H, and Sun Y (2001). Elevated expression of SAG/ROC2/ Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but antisense transfection inhibits tumor cell growth. Mol Carcinog 30, 62-70.
70. Jia L, Soengas MS, and Sun Y (2009). ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 69, 4974-4982.
71. Jia L, Yang J, Hao X, Zheng M, He H, Xiong X, Xu L, and Sun Y (2010). Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res 16, 814-824.
72. Sun Y (1999). Alterations of SAG mRNA in human cancer cell lines: requirement for the RING finger domain for apoptosis protection. Carcinogenesis 20, 1899-1903.
73. Yang ES and Park JW (2006). Regulation of nitric oxide-induced apoptosis by sensitive to apoptosis gene protein. Free Radic Res 40, 279-284.
74. +)-induced cytotoxicity via the downregulation of ROS generation and JNK signaling. Neurosci Lett 413, 132-136.
75. Lee SJ, Yang ES, Kim SY, Shin SW, and Park JW (2008). Regulation of heat shock-induced apoptosis by sensitive to apoptosis gene protein. Free Radic Biol Med 45, 167-176.
76. He H, Gu Q, Zheng M, Normolle D, and Sun Y (2008). SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis 29, 858-865.
77. Chanalaris A, Sun Y, Latchman DS, and Stephanou A (2003). SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol 35, 257-264.
78. Kim DW, Lee SH, Jeong MS, Sohn EJ, Kim MJ, Jeong HJ, An JJ, Jang SH, Won MH, Hwang IK, et al. (2010). Transduced Tat-SAG fusion protein protects against oxidative stress and brain ischemic insult. Free Radic Biol Med 48, 969-977.
79. Yang GY, Pang L, Ge HL, Tan M, Ye W, Liu XH, Huang FP, Wu DC, Che XM, Song Y, et al. (2001). Attenuation of ischemia-induced mouse brain injury by SAG, a redox-inducible antioxidant protein. J Cereb Blood Flow Metab 21, 722-733.
80. Wilson GD (2004). Radiation and the cell cycle, revisited. Cancer Metastasis Rev 23, 209-225.
81. Jia L, Bickel JS, Wu J, Morgan MA, Li H, Yang J, Yu X, Chan RC, and Sun Y (2011). RBX1 (RING box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins. J Biol Chem 286, 3379-3386.
82. Swaroop M, Bian J, Aviram M, Duan H, Bisgaier CL, Loo JA, and Sun Y (1999). Expression, purification, and biochemical characterization of SAG, a RING finger redox-sensitive protein. Free Radic Biol Med 27, 193-202.
83. Tan M, Zhu Y, Kovacev J, Zhao Y, Pan ZQ, Spitz DR, and Sun Y (2010). Disruption of Sag/Rbx2/Roc2 induces radiosensitization by increasing ROS levels and blocking NF-κB activation in mouse embryonic stem cells. Free Radic Biol Med 49, 976-983.
84. Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, and Eymin B (2007). Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J Pathol 213, 303-310.
85. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, Dairkee SH, Wernick M, Collins C, and Smith HS (1998). The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 58, 3677-3683.
86. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM, Honrado E, Campoverde A, Palacios J, Nathanson KL, Garcia MJ, and Benitez J (2009). Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 11, R86.
87. Schindl M, Gnant M, Schoppmann SF, Horvat R, and Birner P (2007). Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res 27, 949-952.
88. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, and Inazawa J (2002). TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 35, 1476-1484.
89. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, and You L (2011). Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med 15, 350-358.
90. Gupta A, Yang LX, and Chen L (2002). Study of the G2/M cell cycle checkpoint in irradiated mammary epithelial cells overexpressing Cul-4A gene. Int J Radiat Oncol Biol Phys 52, 822-830.
91. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, Smith PG, Morgan MA, and Sun Y (2012). Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 72, 282-293.
92. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, and Mori M (2002). Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62, 3819-3825.
93. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, and Hershko DD (2005). The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 103, 1336-1346.
94. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, and Pagano M (2002). Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 110, 633-641.
95. Wang XC, Tian LL, Tian J, and Jiang XY (2012). Overexpression of SKP2 promotes the radiation resistance of esophageal squamous cell carcinoma. Radiat Res 177, 52-58.
96. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, et al. (2008). Targeting the p27 E3 ligase SCF(Skp2) results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111, 4690-4699.
97. Kudo Y, GuardavaccaroD, Santamaria PG, Koyama-Nasu R, Latres E, Bronson R, Yamasaki L, and PaganoM(2004). Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol 24, 8184-8194.
98. Belaidouni N, Peuchmaur M, Perret C, Florentin A, Benarous R, and Besnard-Guerin C (2005). Overexpression of human β TrCP1 deleted of its F box induces tumorigenesis in transgenic mice. Oncogene 24, 2271-2276.
99. Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, and Fuchs SY (2005). Targeting β-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res 65, 1904-1908.
100. Muerkoster S, Arlt A, Sipos B, Witt M, Grossmann M, Kloppel G, Kalthoff H, Folsch UR, and Schafer H (2005). Increased expression of the E3-ubiquitin ligase receptor subunit βTRCP1 relates to constitutive nuclear factor-κB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 65, 1316-1324.
101. β-TrCPE3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia 8, 1042-1054.
102. Deorukhkar A and Krishnan S (2010). Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 80, 1904-1914.
103. Soldatenkov VA, Dritschilo A, Ronai Z, and Fuchs SY (1999). Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res 59, 5085-5088.
104. Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, Ouni I, Pierce N, Tang X, Lomenick B, et al. (2010). Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol 28, 738-742.
105. Orlicky S, Tang X, Neduva V, Elowe N, Brown ED, Sicheri F, and Tyers M (2010). An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol 28, 733-737.
106. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, et al. (2010). Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 37, 102-111.
107. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, et al. (2010). MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma. Blood 116, 1515-1523.
108. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, et al. (2010). Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115, 3796-3800.
109. Tan M, Li Y, Yang R, Xi N, and Sun Y (2011). Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. PLoS One 6, e27726.
110. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, and Amidon B (2011). Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 71, 3042-3051.
111. Jia L, Li H, and Sun Y (2011). Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 13, 561-569.
112. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379.
113. Lin JJ, Milhollen MA, Smith PG, Narayanan U, and Dutta A (2010). NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 70, 10310-10320.
114. Soucy TA, Dick LR, Smith PG, Milhollen MA, and Brownell JE (2010). The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 1, 708-716.
115. Soucy TA, Smith PG, and Rolfe M (2009). Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 15, 3912-3916.
116. Goktas S, Baran Y, Ural AU, Yazici S, Aydur E, Basal S, Avcu F, Pekel A, Dirican B, and Beyzadeoglu M (2010). Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology 75, 793-798.
117. Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, et al. (2008). Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med 14, 1118-1122.
118. Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, Andrews D, Curran WJ Jr, and Dicker AP (2009). Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 74, 433-439.
119. Yang D, Tan M, Wang G, and Sun Y (2012). The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One 7, e34079.
120. Skaar JR, D'Angiolella V, Pagan JK, and Pagano M (2009). SnapShot: F box proteins II. Cell 137, 1358. e1-1358. e2.
121. Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, et al. (2012). Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell 21, 388-401.
122. Toth JI, Yang L, Dahl R, and Petroski MD (2012). A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. Cell Rep 1, 309-316.
123. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
124. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis M, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
125. Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K, and Lightcap ES (2011). Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics 10, M111.009183.
126. Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, Guo A, Chen YN, Rush J, Hsu PW, et al. (2011). Global identification of modular cullin-RING ligase substrates. Cell 147, 459-474.
127. Lee JE, Sweredoski MJ, Graham RL, Kolawa NJ, Smith GT, Hess S, and Deshaies RJ (2011). The steady-state repertoire of human SCF ubiquitin ligase complexes does not require ongoing Nedd8 conjugation. Mol Cell Proteomics 10, M110.006460.
128. Bennett EJ, Rush J, Gygi SP, and Harper JW (2010). Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 143, 951-965.
129. Jung J, Kim EJ, Chung HK, Park HJ, Jeong SY, and Choi EK (2012). c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer. Int J Oncol 40, 385-390.
130. Warren G, Grimes K, Xu Y, Kudrimoti M, and St Clair W (2006). Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition. Oncol Rep 15, 1287-1291.
131. Munshi A, Kurland JF, Nishikawa T, Chiao PJ, Andreeff M, and Meyn RE (2004). Inhibition of constitutively activated nuclear factor-κB radiosensitizes human melanoma cells. Mol Cancer Ther 3, 985-992.